Avandia - News About Avandia - Page 1

Stories

17 Stories

June 2008
- 8 Meds Docs Won't Take
  
  Men's Health | Jun 23, 08 7:55 PM CDT
  
  (Newser) - Some drugs have such serious drawbacks that even doctors won’t take them, Men’s Health reports. The big eight: Advair: Can actually increase the severity of asthma attacks Avandia: Diabetes drug carries risk of heart attack More »
April 2008
- Serious Side Effects Linked to Avandia, Fosamax
  
  Reuters | Apr 29, 08 2:57 AM CDT
  
  (Newser) - Two new studies have linked the popular prescription drugs Fosamax and Avandia to serious side effects, Reuters reports. Fosamax, prescribed for osteoporosis, has been tied to a type of abnormal heartbeat that can cause dizziness and fatigue. Another study links Avandia, used to treat diabetes, to a double or even triple risk of broken limbs after long-term use. More »
July 2007
- FDA Panel Votes to Keep Avandia on Shelves
  
  Wall Street Journal | Jul 30, 07 5:38 PM CDT
  
  (Newser) - An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs. More »
- Dow Sinks Further on Credit Jitters
  
  Wall Street Journal | Jul 27, 07 4:10 PM CDT
  
  (Newser) - Stocks tumbled more than 200 points for the second day in a row, on fears that small-cap securities might be especially hard hit by a possible collapse in certain financial services. The Dow was down 208.10 to 13265.47, despite a report that the GDP grew faster this quarter than it has in a year—but the Russell 2000, which measures small stocks, dipped 1.7% into negative territory for the year. More »
June 2007
- Controversy Rages Over Diabetes Drug's Heart Risks
  
  New York Times | Jun 6, 07 12:16 PM CDT
  
  (Newser) - Troubling questions about the diabetes drug Avandia persisted yesterday as an FDA official revealed that she was barred from recommending a critical warning about the medication, the Times reports. In the run-up to congressional hearings that began today, manufacturer GlaxoSmithKline rushed to disseminate interim clinical findings in hopes of blunting the controversy. More »
May 2007
- Glaxo Stems Stock Slide Over Avandia
  
  Daily Telegraph (UK) | May 31, 07 6:44 AM CDT
  
  (Newser) - Glaxo shares pulled out of a tailspin after the pharma giant defended its second biggest selling drug, Avandia, against claims that it triggers heart attacks. A sharply worded letter from the company's chief medical officer on the website of medical journal The Lancet pointed out that the increased incidence of heart attacks among Avandia patients—0.6%—was still very small. More »
- FDA Warned of Avandia Risks Years Ago
  
  New York Times | May 24, 07 1:56 PM CDT
  
  (Newser) - A diabetes doctor warned the FDA of heart risks posed by the diabetes drug Avandia seven years ago, the New York Times reports. The same concerns raised by Dr. John Buse in a 2000 letter were reiterated in a study published by cardiologist Steven Nissen this week. More »
- Drug Company Nemesis Strikes Again
  
  Wall Street Journal | May 22, 07 1:32 PM CDT
  
  (Newser) - The doctor who helped to raise concerns about the painkiller Vioxx is back—with the study released earlier this week linking the same company's popular diabetes drug, Avandia, to higher risk of heart attacks. The Wall Street Journal looks at 58-year-old cardiologist Steven Nissen's role in identifying and publicizing drug risks. More »
- Diabetes Drug Ups Heart Risk
  
  Associated Press | May 21, 07 3:15 PM CDT
  
  (Newser) - A popular diabetes drug may increase heart attack risks, a study reported in the New England Journal of Medicine concludes. Patients who took Avandia, which treats Type 2 diabetes, were 43% more likely to have a heart attack than those who took a placebo, the Cleveland Clinic study found. More »
September 2006
- Diabetes Drug Also Preventive; Avandia Reduces Risk of Developing Disease, Study Finds
  
  Washington Post | Sep 16, 06
  
  The largest diabetes-prevention study ever done has found that a drug already used to treat the disease can also help keep "pre- diabetics" from developing it. But many experts said losing weight and exercising remain a safer, cheaper approach. The drug, rosiglitazone, or Avandia, appeared to cut the risk of developing Type 2 diabetes by more than half, doctors reported yesterday. Type 2 is the most common form of diabetes, afflicting more than 200 million people worldwide.
March 2004
- New Data Support the Potential Cardiovascular Benefits of Avandia
  
  PR Newswire | Mar 9, 04
  
  Data presented at the 53rd Annual Scientific Session of the American College of Cardiology (ACC) demonstrated that the insulin sensitizer Avandia (rosiglitazone maleate) may have certain cardiovascular benefits for patients with type 2 diabetes:
June 2003
- Patients sue Glaxo over drugs danger warning
  
  Evening Standard (UK) | Jun 20, 03
  
  DRUGS giant GlaxoSmithKline is facing legal action in the US over claims that it failed to warn patients its high-selling insulin drug Avandia could cause heart and liver failure. The product liability suit was brought on behalf of 24 Californian and eight Texan diabetes patients, some of whom claim they needed liver transplants just weeks after starting the drug.